The Role of Insulin-like Growth Factor I in Mechanisms of Resilience and Vulnerability to Sporadic Alzheimer’s Disease

• Published in: International journal of molecular sciences 2023-11, Vol.24 (22), p.16440
• Main Authors: Zegarra-Valdivia, Jonathan A, Pignatelli, Jaime, Nuñez, Angel, Torres Aleman, Ignacio
• Format: Article
• Language: English
• Subjects: Advertising executives; Alzheimer's disease; Brain; Cognition & reasoning; Cytokines; Health aspects; Health risk assessment; Inflammation; Injuries; Insulin; insulin-like growth factor I; Insulin-like growth factors; Lifestyles; Medical research; Medicine, Experimental; Oxidative stress; Pathology; Peptides; Post traumatic stress disorder; Risk factors; Traumatic brain injury; Type 2 diabetes; vulnerability and resilience
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms242216440

Despite decades of intense research, disease-modifying therapeutic approaches for Alzheimer’s disease (AD) are still very much needed. Apart from the extensively analyzed tau and amyloid pathological cascades, two promising avenues of research that may eventually identify new druggable targets for AD are based on a better understanding of the mechanisms of resilience and vulnerability to this condition. We argue that insulin-like growth factor I (IGF-I) activity in the brain provides a common substrate for the mechanisms of resilience and vulnerability to AD. We postulate that preserved brain IGF-I activity contributes to resilience to AD pathology as this growth factor intervenes in all the major pathological cascades considered to be involved in AD, including metabolic impairment, altered proteostasis, and inflammation, to name the three that are considered to be the most important ones. Conversely, disturbed IGF-I activity is found in many AD risk factors, such as old age, type 2 diabetes, imbalanced diet, sedentary life, sociality, stroke, stress, and low education, whereas the Apolipoprotein (Apo) E4 genotype and traumatic brain injury may also be influenced by brain IGF-I activity. Accordingly, IGF-I activity should be taken into consideration when analyzing these processes, while its preservation will predictably help prevent the progress of AD pathology. Thus, we need to define IGF-I activity in all these conditions and develop a means to preserve it. However, defining brain IGF-I activity cannot be solely based on humoral or tissue levels of this neurotrophic factor, and new functionally based assessments need to be developed.